Based on this YouTube video's total view count of 280K views and industry-standard rates, the estimated total earning is $196 - $561 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

Explore Retatrutide GLP-1 Isn't Approved. MILLIONS Are Already Using It RIGHT NOW. with 280,519 views, 2,570 likes, and 628 comments. Experience the impact of this video content that has captured audience attention.

Retatrutide could become the most powerful weight-loss drug yet, and it may push obesity treatment into completely new territory. Unlike Ozempic and Wegovy, which primarily target GLP-1, Retatrutide activates three hormone pathways at once: GLP-1, GIP, and glucagon. That combination is what makes it different. GLP-1 suppresses appetite. GIP helps regulate how the body processes incoming energy. And glucagon may push the body toward releasing stored fuel rather than simply consuming less of it. The results have attracted enormous attention. Clinical trials have reported average weight loss approaching 30% of total body weight at the highest doses-levels that begin to resemble outcomes traditionally associated with bariatric surgery. But Retatrutide is still investigational. Researchers are continuing to study its long-term safety, including effects on heart rate, muscle loss, and neurological symptoms such as dysesthesia. Meanwhile, unapproved versions are already being sold online, despite having no legitimate quality control or guarantee that the vial contains what the label claims. That creates two very different stories. Inside controlled clinical trials, Retatrutide could represent a major advance in metabolic medicine. Outside them, it becomes an uncontrolled experiment. So is Retatrutide really the “King Kong” of weight-loss drugs? The early data is extraordinary, but the safety story is still being written. 01:37 - How Ozempic Changed the Science of Obesity 05:16 - Why Retatrutide Targets Three Hormones at Once 08:01 - How Retatrutide Forces the Body to Burn Fat 13:27 - The Gila Monster Discovery Behind GLP-1 Drugs 17:22 - The Billion-Dollar Race Between Novo Nordisk and Eli Lilly 18:33 - The Clinical Trials That Put Retatrutide Ahead 21:29 - Heart Risks, Muscle Loss and New Side Effects 23:59 - The Dangerous Gray Market for Unapproved Retatrutide Narrated by: Josh Risser 🔔 Don't forget to SUBSCRIBE! 🔔 SUGGEST A TOPIC: https://bit.ly/suggest-an-infographics-video 💬 Come chat with me: https://discord.gg/theinfoshow 🔖 MY SOCIAL PAGES TikTok ► https://www.tiktok.com/@theinfographicsshow Facebook ► https://www.facebook.com/TheInfographicsShow 📝 SOURCES: https://pastebin.com/ZhXW51Wd All videos are based on publicly available information unless otherwise noted.

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.